Searched for
DIVIS EXPANSION PLANS
Vedanta, Divi’s, Bajaj Holdings, BEL, IndiGo among top wealth creator in FY25Vedanta led NSE 100's FY25 performance with an 87% TSR, driven by share price appreciation and dividends. Divi’s Laboratories, Bajaj Holdin...- Don't stress on index; take home some money on metals and PSUs before June 4: Sanjiv BhasinSanjiv Bhasin of IIFL Securities believes HDFC Bank will remain a market leader even during a market correction. He suggests taking profits...
- 268 companies set to release Q2 results on Monday. What to expect from Nykaa, Divi’s Labs and Varun BeveragesMax Healthcare Institute, NHPC, Bharat Forge, Hindustan Petroleum Corporation, Gland Pharma, Emami, Exide Industries, R R Kabel, Bajaj Elec...
- Will Divi's business expansion boost its valuations?Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companie...
- Gurmeet Chadha on top 3 new holdings in portfolio“Since we launched the PMS, the top new holdings in our portfolio include Reliance where we think what has happened to Jio would happen to ...
- Abhay Agarwal on why he added Divi's, LTI and Lemon Tree to his portfolio now“There were some stocks that we always wanted to buy but we found them to be expensive. In this correction, we have got the opportunity to ...
- Glenmark Life IPO kicks off: Here's what makes analysts bullish on the issueAnalysts are positive on the company's prospects, given that China Plus One strategy by global formulation makers -- to de-risk their procu...
- India’s best-performing stock is seeing a wave of optimistic callsThe optimism is stemming from the company’s capacity-expansion plans and potential to win more business as India cuts its reliance on Chine...
- Saurabh Mukherjea reveals his 3 favourite pharma stocksOver a two-three-year period, the pricing power in API space will ebb away and margins will come back down, says Saurabh Mukherjea.
- What makes the latest pharma company to enter Nifty very different from its peers in the index?Unlike its peers, Divi is a pure-play active pharma ingredients (API) company and does not face the same challenges and risks as that of it...
- Stocks in the news: Divi's Labs, SBI Life, ZEEL, IRCTC, Bharti Infratel, Hindalco and PNBThe dedicated bankruptcy court has decided to appoint an IRP in a case filed by lender State Bank of India (SBI) against Anil Ambani.
- Buy Divi's Laboratories, target Rs 1,600: Axis CapitalBuy Divi's Laboratories Ltd. at a price target of Rs 1600.
- Not biggies, go for these niche pharma cos: Dipan MehtaBuy contract manufacturing pharma companies on correction, says Mehta.
- Neutral on Divi's Laboratories, target Rs 1200: Motilal OswalNeutral Divi's Laboratories Ltd. at a price target of Rs 1200.0 .
- Divis to spend Rs 300 crore on expansion plans in 2018The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during th...
- Top stocks in focus on Monday, 14 August 2017Here is a list of top stocks that are likely to be in focus in today's trading session.
- Managing LAP, affordable home growth key for HFCsHowever, after a sharp jump in stock prices over the past year, valuations appear to be rich.
- Divi's Labs: Short term pain, long term positiveThe stock of drug firm Divi's Labs has corrected 12% since the company announced its March quarter at the beginning of this week.
- Divis Labs will maintain stable growth momentum and benefit from weak rupeeThe company is ahead of its peers in margin growth and has recorded a consistent revenue growth of above 30% for the past five quarters.
- Drug formulations pep up sector, but contract research spoils Q3 partyHowever, pharma companies mainly into formulations have managed to show strong growth, except for those who had operations in Germany and s...
Load More
